Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Physiol.

Sec. Respiratory Physiology and Pathophysiology

Volume 16 - 2025 | doi: 10.3389/fphys.2025.1679278

Insulin-like Growth Factor Family and its Impact on Pulmonary Arterial Hypertension: A Review

Provisionally accepted
  • 1Shandong Second Medical University, Weifang, China
  • 2Qingdao University, Qingdao, China
  • 3Qingdao Municipal Hospital, Qingdao, China
  • 4University of Health and Rehabilitation Sciences, Qingdao, China

The final, formatted version of the article will be published soon.

Pulmonary arterial hypertension (PAH) is a progressive and life-threatening cardiopulmonary disorder with rising global prevalence and limited curative options. Although current therapies have improved clinical outcomes, they primarily offer symptomatic relief, underscoring the need for novel disease-modifying strategies. PAH pathogenesis involves multiple interrelated mechanisms, including genetic predisposition, endothelial dysfunction, inflammation, oxidative stress, and vascular remodeling. Among these, endothelial dysfunction and vascular remodeling are central to both disease initiation and progression. Endothelial dysfunction is an early and central event, leading to an imbalance between vasodilators and vasoconstrictors, increased vascular permeability, and a pro-thrombotic state. These changes initiate a cascade of vascular remodeling, characterized by pulmonary artery smooth muscle cell proliferation, fibroblast activation, and extracellular matrix deposition, ultimately resulting in increased vascular resistance and right ventricular failure. Recent evidence indicates that the insulin-like growth factor (IGF) family significantly contributes to both vascular remodeling and endothelial dysfunction in PAH. Through complex signaling networks involving IGF receptors and regulatory proteins, IGFs promote smooth muscle cell proliferation, extracellular matrix accumulation, and endothelial cell dysfunction — aggravating vascular alterations characteristic of the disease. While the IGF family — including IGFs, IGFBPs, and IGFBPLs—has been implicated in a range of cardiovascular disorders, its specific involvement in PAH remains insufficiently characterized. This review consolidates current evidence on the IGF family's roles in PAH pathogenesis, with emphasis on its contributions to vascular remodeling, endothelial dysfunction, and right ventricular adaptation. By delineating the distinct yet interconnected actions of IGF-related molecules, this review aims to identify potential diagnostic biomarkers and therapeutic targets, ultimately advancing precision strategies for PAH management.

Keywords: pulmonary arterial hypertension, Insulin-like growth factor, Insulin-like GrowthFactor Binding Protein, Insulin-like Growth Factor Binding Protein-Like, Pathogenicmechanisms

Received: 04 Aug 2025; Accepted: 03 Oct 2025.

Copyright: © 2025 Li, Mo and Dai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Hongyan Dai, drdaihy@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.